{"id":180,"date":"2019-12-25T09:22:48","date_gmt":"2019-12-25T06:22:48","guid":{"rendered":"https:\/\/www.epigendx.online\/?page_id=180"},"modified":"2019-12-25T10:00:22","modified_gmt":"2019-12-25T07:00:22","slug":"technology","status":"publish","type":"page","link":"https:\/\/www.epigendx.online\/en\/technology\/","title":{"rendered":"Technology"},"content":{"rendered":"

[vc_row el_id=”top”][vc_column][vc_row_inner][vc_column_inner width=”5\/6″][vc_column_text]

<\/div>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/6″][vc_column_text]<\/p>\n

\"Print<\/a><\/div>\n
<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”3\/5″][vc_column_text]Recently Sibenzyme subsidiary company Epigene LLC has finished R&D on the epigenetic tests for early detection of lung, breast and stomach cancer and Epigenlab LLC has finished R&D on a new epigenetic PCR test for early detection of renal cancer.
\nIn the tests we analyze DNA isolated from the vein blood and use a standard real-time PCR machine.
\nWe are planning to launch the clinical trials and registration in Russia soon<\/p>\n

During R&D stage we achieved more than 90% sensitivity and specificity of the tests.<\/p>\n

Research was supported by Ministry of Science and Education of the Russian Federation and Skolkovo Foundation.<\/p>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/5″][vc_single_image image=”99″ img_size=”medium” alignment=”center”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row full_height=”yes” columns_placement=”top” equal_height=”yes” content_placement=”top” css=”.vc_custom_1574828545065{background-color: #e5ebff !important;}”][vc_column][vc_column_text]<\/p>\n

What is special in our tests and approach?<\/h2>\n

[\/vc_column_text][vc_column_text]<\/p>\n

We determine DNA methylation markers<\/mark>, but our DNA methylation assay is absolutely new.<\/mark><\/p>\n

\n
\n

Assay is based on a new type of enzymes<\/mark>, recently developed by SibEnzyme – methyl-directed DNA endonucleases or MD DNA endonucleases. MD endonucleases work like traditional restriction enzymes, but, on the contrary, they cut only methylated DNA and may be used in epigenetic studies. More details<\/a><\/p>\n<\/div>\n

\n

GLAD-PCR assay<\/mark> – is a simple and inexpensive method for epigenetic studies of DNA preparations from clinical samples. It allows to detect even several DNA molecules with R(5mC)GY site of interest<\/mark> in a presence of excessive amount of unmethylated DNA. Just 3 easy steps in one tube. More details<\/a><\/p>\n<\/div>\n

\n

Genomic DNA fragmentation with GlaI<\/mark> and subsequent NGS<\/mark> allow to construct a map of R(5mC)GY sites in analyzed genomes of patients and healthy donors. Comparison of these maps reveals R(5mC)GY sites – potential epigenetic markers<\/mark> that can be used for diagnostics. More details<\/a><\/p>\n<\/div>\n

\n

Light fraction of the blood cells<\/mark> is a good source of DNA for our PCR tests. It’s easy to prepare this fraction \u2013 one standard table centrifuge, no reagents except saline and minimal time of manipulation with a blood. More details<\/a><\/p>\n<\/div>\n<\/div>\n

Conferences, patents and publications<\/a><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_height=”yes” css_animation=”fadeInUp” el_id=”MD”][vc_column][vc_column_text]<\/p>\n

<\/div>\n

New type of enzymes – MD DNA endonucleases<\/h2>\n

[\/vc_column_text][vc_row_inner][vc_column_inner width=”2\/3″][vc_column_text]Methyl-directed site-specific DNA endonucleases belong to a new type of enzymes discovered by SibEnzyme (Russia).<\/p>\n

These enzymes are very similar to restriction enzymes in biochemical properties and cleave DNA completely. A principal difference of new type of enzymes is that they cleave only methylated DNA. This property makes MD endonucleases a good instrument for epigenetic analysis.<\/p>\n

Now\u00a0 9 different MD DNA-endonucleases are commercially available<\/a>. Recognition sites of MD enzymes differ in DNA structure and methylation patterns plus the enzymes may cleave the same recognition site in a different way.<\/p>\n

A special advantage of GlaI<\/a> recognition site R(5mC)GY – this site is the same as a product of DNA methylation with DNMT3 which is responsible for DNA methylation de novo<\/em>. It makes GlaI a very convenient tool for epigenetic diagnostics<\/p>\n

Known applications:<\/p>\n